Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 2;11:15606. doi: 10.1038/s41598-021-95201-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Kaplan–Meier curves of the composite endpoint “switch from ER-Tac”, “graft failure”, or “death” as first event by metabolism group starting from three months after RTx (a). Overall survival is shown in (b). Cumulative incidence of the “graft failure” component (c) and “switch from ER-Tac” (c) of the composite endpoint. Since only one death without prior switch or graft failure occurred in the slow metabolism group, the curves were not drawn. The impact of fast vs. slow metabolizer was thus estimated using Fine and Gray's model leading to subdistribution hazard ratios (sub-HR) on the components of the composite endpoint. Cumulative incidence was estimated using the Aalen-Johansen estimator. Gray's k-sample test was applied to compare the cumulative incidence of the corresponding event type. The combined endpoint “switch/graft failure/death” showed more events in the fast metabolizer group. Competing risk analysis revealed that “switch from ER-Tac” occurred more frequently in fast than in slow metabolizers, but no differences were found in regards to graft failure or overall survival.